The stock of ARS Pharmaceuticals Inc (NASDAQ: SPRY) has increased by 7.66 when compared to last closing price of 13.05. Despite this, the company has experienced a 17.08% gain in its stock price over the last five trading sessions. accesswire.com reported 2024-09-18 that LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
The 36-month beta value for SPRY is at 0.89. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SPRY is 48.76M, and currently, shorts hold a 22.48% of that float. The average trading volume for SPRY on September 19, 2024 was 1.09M shares.
SPRY’s Market Performance
SPRY’s stock has seen a 17.08% increase for the week, with a -1.33% drop in the past month and a 73.89% gain in the past quarter. The volatility ratio for the week is 5.91%, and the volatility levels for the past 30 days are at 6.77% for ARS Pharmaceuticals Inc The simple moving average for the last 20 days is 10.17% for SPRY stock, with a simple moving average of 60.00% for the last 200 days.
Analysts’ Opinion of SPRY
Raymond James, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $22, previously predicting the price at $18. The rating they have provided for SPRY stocks is “Strong Buy” according to the report published on August 13th, 2024.
Leerink Partners gave a rating of “Outperform” to SPRY, setting the target price at $20 in the report published on August 12th of the current year.
SPRY Trading at 19.61% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.85% of loss for the given period.
Volatility was left at 6.77%, however, over the last 30 days, the volatility rate increased by 5.91%, as shares sank -5.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.95% upper at present.
During the last 5 trading sessions, SPRY rose by +17.08%, which changed the moving average for the period of 200-days by +190.89% in comparison to the 20-day moving average, which settled at $12.71. In addition, ARS Pharmaceuticals Inc saw 156.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from ERIC KARAS, who proposed sale 10,000 shares at the price of $14.00 back on Sep 18 ’24. After this action, ERIC KARAS now owns shares of ARS Pharmaceuticals Inc, valued at $140,000 using the latest closing price.
Tanimoto Sarina, the CHIEF MEDICAL OFFICER of ARS Pharmaceuticals Inc, sale 100,000 shares at $11.50 during a trade that took place back on Sep 10 ’24, which means that Tanimoto Sarina is holding 1,396,494 shares at $1,149,775 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -120.71 for the present operating margin
- 0.87 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -95.37. The total capital return value is set at -0.26. Equity return is now at value -19.34, with -18.66 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -275.98. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -15.12.
Currently, EBITDA for the company is -67.45 million with net debt to EBITDA at 0.64. When we switch over and look at the enterprise to sales, we see a ratio of 2820.35. The receivables turnover for the company is 0.83for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 32.78.
Conclusion
In conclusion, ARS Pharmaceuticals Inc (SPRY) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
